Low-molecular-weight heparin overdose: management by observation. - Wikidata - wikimedia - TriplyDB

Low-molecular-weight heparin overdose: management by observation.

Low-molecular-weight heparin overdose: management by observation.

http://www.wikidata.org/entity/Q37798093

about

Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.Emergency Neurological Life Support: Pharmacotherapy.Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19.Inadvertent Overdose of Low-Molecular-Weight Heparin in an Elderly Patient with Deep Vein Thrombosis and Acute Kidney Injury.Pharmacotherapy Pearls for Emergency Neurological Life Support.

P2860

Q26992262-098BDD31-45E4-4BE0-AA35-1458B7B07BD0 Q28079081-3848F0DB-98C5-46C4-8179-B16449B4C300 Q33894433-0D885CF0-B989-4756-9341-F90A4EB15F29 Q38599737-AE6C302F-76B7-4FEE-B5FD-8E142B77718F Q39187267-C4446D3B-20C8-4D0F-AAE0-03350EDF9838 Q40997231-56AB47DB-55DE-45A9-A7AB-22156282D35D Q45067456-61126F66-A72F-4E0E-BC0E-9D42A8E6A3B7

P2860

Low-molecular-weight heparin overdose: management by observation.

http://www.wikidata.org/entity/Q37798093

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Low-molecular-weight heparin overdose: management by observation.

@en

Low-molecular-weight heparin overdose: management by observation.

@nl

type

label

Low-molecular-weight heparin overdose: management by observation.

@en

Low-molecular-weight heparin overdose: management by observation.

@nl

prefLabel

Low-molecular-weight heparin overdose: management by observation.

@en

Low-molecular-weight heparin overdose: management by observation.

@nl

P1433

Q37798093-FEF09D08-F04C-481B-B02C-5C7F683C7B29

P1476

Q37798093-DCB69EA8-ED43-4E7D-A500-919F8C76FE94

P2093

Q37798093-09FB8C11-7B27-4B97-83DB-EB96708661DE

Q37798093-26CF0ADA-CF93-47FD-A961-499E6E2B66B5

Q37798093-BAEF8BB7-3F7A-4593-987E-64AE417C1BF8

P2860

Q37798093-2608D22F-99F9-4E4E-82CA-19E64ABD0E80

Q37798093-2A8A240C-01D5-4E6F-AC95-51B8FB97361F

Q37798093-2D7EF640-6993-4A19-BAAF-BB2C39384F78

Q37798093-50E9B0BC-EC3F-41FA-96ED-2526B07DE801

Q37798093-53D3FA73-27B2-4578-8D82-E1A0B24779D3

Q37798093-70D98D49-08F0-4DFC-80EC-0DE365156FA4

Q37798093-72AC92A9-EFC6-4412-9406-CAD178D1CD18

Q37798093-74CA15B0-CA87-4617-A0C7-0E61E55FCD95

Q37798093-78F689DB-EDA7-4BAA-986C-7AF033BF13BF

Q37798093-815FCD17-FFE9-45BE-806C-E88DEDE6F48C

P304

Q37798093-4B8B3A30-61BC-47C4-8E80-35FE3E0ABFE3

P31

Q37798093-5E2535E6-0690-48D1-85E8-AE478336B69F

P356

Q37798093-E36A0968-400D-4572-9AF5-500591529BCF

P407

Q37798093-C92D79E0-CA9C-4C67-9E2F-BA60949EFB99

P433

Q37798093-B7B43C05-9B79-4D00-9B50-99DDA6130ACE

P478

Q37798093-0F98054E-36AF-44F4-A9FB-B03C31E85DB8

P577

Q37798093-60545883-EE21-43E6-927A-1B4FA1E54E42

P698

Q37798093-41A25BC6-23FA-4DB3-B1AD-DCEBAE0F84CE

P921

Q37798093-83268AE7-7402-4AC7-AE49-6A35E8F7B959

P356

P1433

Annals of Pharmacotherapy

P1476

Low-molecular-weight heparin overdose: management by observation.

@en

P2093

Andrew A Monte

http://www.w3.org/2001/XMLSchema#string

Michael Bodmer

http://www.w3.org/2001/XMLSchema#string

Tammi H Schaeffer

http://www.w3.org/2001/XMLSchema#string

P2860

Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.

Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.

Serious anaphylactic reactions due to protamine sulfate: a systematic literature review.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.

Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.

Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

P304

1836-1839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1P318

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20923945

http://www.w3.org/2001/XMLSchema#string

P921